Natera: Signatera Cancer Test with Historic Expansion to Japan
Reading Time: 3 minutes
Natera's business model is based on genetic testing through non-invasive blood analyses used in oncology, women's health, and transplantation medicine. By analyzing circulating free DNA (cfDNA), the company enables precise diagnostics to guide individualized treatment plans. Signatera received approval in June as the first MRD test in Japan, initially for the treatment of colorectal cancer patients. In the first quarter, the business grew by 39% and reached a record volume with 1 million processed tests. The stock is trading at an all-time...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
